These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12676167)

  • 1. Left ventricular hypertrophy: virtuous intentions, malign consequences.
    Pokharel S; Sharma UC; Pinto YM
    Int J Biochem Cell Biol; 2003 Jun; 35(6):802-6. PubMed ID: 12676167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology of chronic heart failure.
    Francis GS
    Am J Med; 2001 May; 110 Suppl 7A():37S-46S. PubMed ID: 11334774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of left ventricular hypertrophy in human hypertension.
    Kahan T
    J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis.
    Luo JD; Zhang WW; Zhang GP; Guan JX; Chen X
    Clin Exp Pharmacol Physiol; 1999 Nov; 26(11):903-8. PubMed ID: 10561812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
    Ikeda Y; Nakamura T; Takano H; Kimura H; Obata JE; Takeda S; Hata A; Shido K; Mochizuki S; Yoshida Y
    J Lab Clin Med; 2000 Apr; 135(4):353-9. PubMed ID: 10779052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro.
    Kojima M; Shiojima I; Yamazaki T; Komuro I; Zou Z; Wang Y; Mizuno T; Ueki K; Tobe K; Kadowaki T
    Circulation; 1994 May; 89(5):2204-11. PubMed ID: 8181146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moexipril and left ventricular hypertrophy.
    Chrysant GS; Nguyen PK
    Vasc Health Risk Manag; 2007; 3(1):23-30. PubMed ID: 17583172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of the renin-angiotensin system in reversal of left ventricular hypertrophy.
    Dahlöf B
    J Hypertens Suppl; 1993 Apr; 11(3):S29-35. PubMed ID: 8315516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of left ventricular hypertrophy: do antihypertensive classes differ?
    Sheridan DJ
    J Hypertens Suppl; 2000 Jul; 18(3):S21-7. PubMed ID: 10952084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BMP-7 attenuates left ventricular remodelling under pressure overload and facilitates reverse remodelling and functional recovery.
    Merino D; Villar AV; García R; Tramullas M; Ruiz L; Ribas C; Cabezudo S; Nistal JF; Hurlé MA
    Cardiovasc Res; 2016 Jun; 110(3):331-45. PubMed ID: 27068510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertrophy to failure.
    Tanser PH
    J Hum Hypertens; 1994 Sep; 8 Suppl 1():S17-20. PubMed ID: 7807508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diastolic properties in canine hypertensive left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition and angiotensin II type-1 receptor blockade.
    Hayashida W; Donckier J; Van Mechelen H; Charlier AA; Pouleur H
    Cardiovasc Res; 1997 Jan; 33(1):54-62. PubMed ID: 9059528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic L-arginine treatment increases cardiac cyclic guanosine 5'-monophosphate in rats with aortic stenosis: effects on left ventricular mass and beta-adrenergic contractile reserve.
    Bartunek J; Dempsey S; Weinberg EO; Ito N; Tajima M; Rohrbach S; Lorell BH
    J Am Coll Cardiol; 1998 Aug; 32(2):528-35. PubMed ID: 9708487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B
    Blood Press Suppl; 1994; 2():35-40. PubMed ID: 8061844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of angiotensin-converting enzyme inhibitor on left ventricular parameters and circulating brain natriuretic peptide in elderly hypertensives with left venticular hypertrophy.
    Kohno M; Minami M; Kano H; Yasunari K; Maeda K; Hanehira T; Yoshikawa J
    Metabolism; 2000 Oct; 49(10):1356-60. PubMed ID: 11079829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
    Carnovali M
    Clin Ter; 2001; 152(2):103-6. PubMed ID: 11441521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The valosin-containing protein is a novel repressor of cardiomyocyte hypertrophy induced by pressure overload.
    Zhou N; Ma B; Stoll S; Hays TT; Qiu H
    Aging Cell; 2017 Oct; 16(5):1168-1179. PubMed ID: 28799247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of in vivo cardiac hypertrophy with insulin-like growth factor-1 and angiotensin-converting enzyme inhibitor: relationship between change in myosin isoform and progression of left ventricular dysfunction.
    Iwanaga Y; Kihara Y; Yoneda T; Aoyama T; Sasayama S
    J Am Coll Cardiol; 2000 Aug; 36(2):635-42. PubMed ID: 10933382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.